» Articles » PMID: 22563438

Downregulation of MiR-92a is Associated with Aggressive Breast Cancer Features and Increased Tumour Macrophage Infiltration

Overview
Journal PLoS One
Date 2012 May 8
PMID 22563438
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Background: MicroRNAs are small non-coding RNAs involved in the regulation of gene expression on a posttranscriptional level. These regulatory RNAs have been implicated in numerous cellular processes and are further deregulated in different cancer types, including breast cancer. MiR-92a is part of the miR-17∼92 cluster, which was first reported to be linked to tumourigenesis. However, little is known about the expression of miR-92a in breast cancer and potential associations to tumour properties. The expression of miR-92a was therefore characterized in 144 invasive breast cancer samples using in situ hybridization and related to clinico-pathological data as well as to selected key properties of the tumour stroma, including the presence of macrophages (CD68) and cancer activated fibroblasts (alpha-SMA).

Methodology/principal Findings: To measure miR-92a levels, an in situ hybridisation protocol was developed and validated using cell lines and miR-92a inhibitors. The expression in the tumour samples was objectively evaluated using digital image analysis program subtracting background activities. We found that the miR-92a expression varied between tumours and was inversely correlated to tumour grade (r = -0.276, p = 0.003) and recurrence-free survival (p = 0.008) and provided independent prognostic information in multivariate Cox analysis (HR: 0.375, CI: 0.145-0.972, p = 0.043). MiR-92a was moreover inversely correlated to the number of infiltrating macrophages in the tumour stroma (r = -0.357, p<0.001), and downregulation of miR-92a promoted cell migration (p<0.01).

Conclusions/significance: This study demonstrates that downregulation of miR-92a in breast cancer is linked to key epithelial and stromal properties as well as clinical outcome.

Citing Articles

MicroRNA-92a-3p Inhibits Cell Proliferation and Invasion by Regulating the Transcription Factor 21/Steroidogenic Factor 1 Axis in Endometriosis.

Zhu J, Xu Z, Wu P, Zeng C, Peng C, Zhou Y Reprod Sci. 2023; 30(7):2188-2197.

PMID: 36650372 PMC: 10310800. DOI: 10.1007/s43032-021-00734-9.


Crosstalk between Tumor-Associated Macrophages and MicroRNAs: A Key Role in Tumor Microenvironment.

Zhou X, Chen B, Zhang Z, Huang Y, Li J, Wei Q Int J Mol Sci. 2022; 23(21).

PMID: 36362044 PMC: 9653885. DOI: 10.3390/ijms232113258.


An Eleven-microRNA Signature Related to Tumor-Associated Macrophages Predicts Prognosis of Breast Cancer.

Jayasingam S, Citartan M, Mat Zin A, Rozhdestvensky T, Tang T, Chng E Int J Mol Sci. 2022; 23(13).

PMID: 35805995 PMC: 9266835. DOI: 10.3390/ijms23136994.


Interpretable Machine Learning Models to Predict the Resistance of Breast Cancer Patients to Doxorubicin from Their microRNA Profiles.

Ogunleye A, Piyawajanusorn C, Goncalves A, Ghislat G, Ballester P Adv Sci (Weinh). 2022; 9(24):e2201501.

PMID: 35785523 PMC: 9403644. DOI: 10.1002/advs.202201501.


Evidence of antagonistic predictive effects of miRNAs in breast cancer cohorts through data-driven networks.

Miglioli C, Bakalli G, Orso S, Karemera M, Molinari R, Guerrier S Sci Rep. 2022; 12(1):5166.

PMID: 35338170 PMC: 8956684. DOI: 10.1038/s41598-022-08737-5.


References
1.
Iorio M, Croce C . MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27(34):5848-56. PMC: 2793003. DOI: 10.1200/JCO.2009.24.0317. View

2.
Shigoka M, Tsuchida A, Matsudo T, Nagakawa Y, Saito H, Suzuki Y . Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int. 2010; 60(5):351-7. DOI: 10.1111/j.1440-1827.2010.02526.x. View

3.
Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

4.
Bonauer A, Dimmeler S . The microRNA-17-92 cluster: still a miRacle?. Cell Cycle. 2009; 8(23):3866-73. DOI: 10.4161/cc.8.23.9994. View

5.
Zhang L, Huang J, Yang N, Greshock J, Megraw M, Giannakakis A . microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A. 2006; 103(24):9136-41. PMC: 1474008. DOI: 10.1073/pnas.0508889103. View